Teachers Advisors LLC lifted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 17.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 88,736 shares of the biopharmaceutical company’s stock after acquiring an additional 13,304 shares during the period. Teachers Advisors LLC owned approximately 0.14% of TG Therapeutics worth $892,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently made changes to their positions in TGTX. Bank of New York Mellon Corp increased its position in shares of TG Therapeutics by 40.7% during the first quarter. Bank of New York Mellon Corp now owns 271,879 shares of the biopharmaceutical company’s stock valued at $3,168,000 after acquiring an additional 78,644 shares in the last quarter. Swiss National Bank grew its position in TG Therapeutics by 18.9% in the 1st quarter. Swiss National Bank now owns 79,200 shares of the biopharmaceutical company’s stock worth $923,000 after purchasing an additional 12,600 shares during the period. Ameriprise Financial Inc. purchased a new position in shares of TG Therapeutics during the 1st quarter worth $1,291,000. Parametric Portfolio Associates LLC purchased a new position in shares of TG Therapeutics during the 1st quarter worth $928,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of TG Therapeutics by 619.5% during the 1st quarter. JPMorgan Chase & Co. now owns 252,870 shares of the biopharmaceutical company’s stock worth $2,946,000 after acquiring an additional 217,724 shares during the last quarter. 49.58% of the stock is owned by institutional investors.
A number of research analysts recently weighed in on TGTX shares. ValuEngine cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $28.00 price target on shares of TG Therapeutics in a research note on Tuesday, October 3rd. Zacks Investment Research downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Finally, BidaskClub upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $25.11.
ILLEGAL ACTIVITY WARNING: “Teachers Advisors LLC Has $892,000 Position in TG Therapeutics, Inc. (TGTX)” was published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.truebluetribune.com/2017/11/14/teachers-advisors-llc-acquires-13304-shares-of-tg-therapeutics-inc-tgtx.html.
Shares of TG Therapeutics, Inc. (NASDAQ TGTX) opened at $8.25 on Tuesday. TG Therapeutics, Inc. has a 52-week low of $4.10 and a 52-week high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.05). TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. analysts predict that TG Therapeutics, Inc. will post -1.79 earnings per share for the current fiscal year.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.